Pneumologie 2019; 73(02): 114
DOI: 10.1055/s-0039-1678399
Abstracts
Georg Thieme Verlag KG Stuttgart · New York

Chronic NTHi-Induced Inflammation Results in Activation of the PD-1 Immune Checkpoint in the Tumor Microenvironment

Felix Ritzmann
Klinik für Innere Medizin V – Pneumologie, Allergologie, Beatmungsmedizin, Universität des Saarlandes
,
Giovanna Vella
Klinik für Innere Medizin V – Pneumologie, Allergologie, Beatmungsmedizin, Universität des Saarlandes
,
Christian Herr
Klinik für Innere Medizin V – Pneumologie, Allergologie, Beatmungsmedizin, Universität des Saarlandes
,
Robert Bals
Klinik für Innere Medizin V – Pneumologie, Allergologie, Beatmungsmedizin, Universität des Saarlandes
,
Christoph Beisswenger
Klinik für Innere Medizin V – Pneumologie, Allergologie, Beatmungsmedizin, Universität des Saarlandes
› Author Affiliations
Further Information

Publication History

Publication Date:
15 February 2019 (online)

 
 

    Microbial colonization contributes to chronic neutrophilic inflammation in COPD. Nontypeable Haemophilus influenzae (NTHi) is frequently found in lungs of stable COPD patients and is the major pathogen triggering exacerbations. Immune-checkpoint inhibitors, such as antibodies targeting the PD-1/PD-L1 axis, have demonstrated efficacy as therapeutic agents for non-small cell lung cancer. Here, we analyzed the activation of the PD-1 immune checkpoint in the tumor microenvironment of mice chronically exposed to NTHi. Mice with an oncogenic Kras allele in lung epithelium were exposed to NTHi for four weeks. The expression of PD-1 and PD-L1 was determined via immunohistochemistry and FACS analysis. Numbers of immune cells were determined in BAL fluids and via immunohistochemistry. Mice were treated with an antibody targeting PD-1 or an isotype antibody. Chronic exposure to NTHi resulted in the recruitment of neutrophils and lymphocytes into the tumor microenvironment, increased membrane expression of PD-L1 in myeloid cells and increased expression of PD-1 in CD4 and CD8 positive lymphocytes. Anti-PD-1 immunotherapy reduced neutrophilic inflammation of the lung. Chronic neutrophilic inflammation induced by NTHi activates the PD-1 immune checkpoint in the tumor microenvironment.


    #